Ginkgo Bioworks Holdings Inc vs TotalEnergies SE — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M), while TotalEnergies SE trades at $87.24 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 251.2× Ginkgo Bioworks Holdings Inc's market cap, and TotalEnergies SE pays a 4.93% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and TotalEnergies SE for 90 Days on average.
| DNA | TTE | |
|---|---|---|
Market Cap | $763.64M | $191.82B |
Volume | 3,204,177 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $15.83 | $93.60 |
52-Week Low | $5.48 | $57.39 |
Typical Hold Time | 7 Days | 90 Days |
Enterprise Value | $865.59M | $222.81B |
Dividend Yield | — | 4.93% |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
TotalEnergies (TTE) trades at $84.23, up 0.3% on the day, with a bearish technical signal from moving averages but recent earnings beats in Q1 and Q2 2026. The stock trades at attractive valuations with a P/E of 10.77 and P/S of 0.96, supported by a 9.08% net income margin. Recent news highlights a $10 billion investment plan in Argentina and a strategic focus on boosting cash flow and dividends through 2030.
The outlook is positive given analyst consensus targets of $95.33 and strong buy ratings (55.88%), though risks include declining revenue trends from 2022-2025 and exposure to oil price volatility. The company's shareholder returns via dividends and buybacks provide support, but investors should monitor execution of growth initiatives amid energy market uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →